AVRO
Price:
$1.4
Market Cap:
$5.24M
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter ...[Read more]
Industry
Biotechnology
IPO Date
2018-06-21
Stock Exchange
NASDAQ
Ticker
AVRO
According to AVROBIO, Inc.’s latest financial reports and current stock price. The company's current ROE is 29.68%. This represents a change of 583.11% compared to the average of 4.34% of the last 4 quarters.
The mean historical ROE of AVROBIO, Inc. over the last ten years is -17.27%. The current 29.68% ROE has changed -271.82% with respect to the historical average. Over the past ten years (40 quarters), AVRO's ROE was at its highest in in the June 2023 quarter at 55.29%. The ROE was at its lowest in in the March 2023 quarter at -45.51%.
Average
-17.27%
Median
-38.36%
Minimum
-140.70%
Maximum
101.86%
Discovering the peaks and valleys of AVROBIO, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 102.55%
Maximum Annual ROE = 101.86%
Minimum Annual Increase = -147.07%
Minimum Annual ROE = -140.70%
Year | ROE | Change |
---|---|---|
2023 | 12.83% | -109.12% |
2022 | -140.70% | 102.55% |
2021 | -69.47% | 49.09% |
2020 | -46.59% | 20.18% |
2019 | -38.77% | 2.17% |
2018 | -37.94% | -147.07% |
2017 | 80.61% | -20.86% |
The current ROE of AVROBIO, Inc. (AVRO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-65.78%
5-year avg
-56.54%
10-year avg
-17.27%
AVROBIO, Inc.’s ROE is greater than CohBar, Inc. (-58.44%), less than Ocean Biomedical, Inc. (75.64%), greater than Enveric Biosciences, Inc. (-201.01%), greater than Elevation Oncology, Inc. (-59.73%), greater than Zura Bio Limited (-39.61%), greater than Hepion Pharmaceuticals, Inc. (-505.74%), less than eFFECTOR Therapeutics, Inc. (2.18%),
Company | ROE | Market cap |
---|---|---|
-58.44% | $1.57M | |
75.64% | $19.50M | |
-201.01% | $3.17M | |
-59.73% | $33.17M | |
-39.61% | $148.87M | |
-505.74% | $3.47M | |
2.18% | $941.00 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AVROBIO, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AVROBIO, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is AVROBIO, Inc.'s ROE?
How is the ROE calculated for AVROBIO, Inc. (AVRO)?
What is the highest ROE for AVROBIO, Inc. (AVRO)?
What is the 3-year average ROE for AVROBIO, Inc. (AVRO)?
What is the 5-year average ROE for AVROBIO, Inc. (AVRO)?
How does the current ROE for AVROBIO, Inc. (AVRO) compare to its historical average?